CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma
CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma
复制标题
CD200R是免疫细胞的共抑制受体，可预测人肝细胞癌的预后
DOI：
10.1016/j.imlet.2016.08.009
复制
发表时间：
2016-10-01
影响因子：
4.4
通讯作者：
Sun, Cheng
中科院分区：
文献类型：
--
作者：
Sun, Haoyu;Xu, Jing;Sun, Cheng
抑制性CD200：CD200受体轴在预防早期微生物感染期间的炎症反应中是必不可少的。据报道，在几种肿瘤模型中，CD200表达与肿瘤进展密切相关，阻断该途径可恢复抗肿瘤反应。本研究首次探讨了CD200：CD200R轴在人肝癌进展和预后中的作用。免疫组化检测肝组织中CD200和CD200R蛋白的表达，发现HCC患者中CD200和CD200R的表达高于健康对照组。CD200主要表达于肝癌的瘤周、瘤周间质和瘤内区域，而CD200R主要表达于瘤周间质。CD200 R蛋白表达强度与肿瘤直径、甲胎蛋白水平呈正相关，病理分级越高、无包膜者CD200 R表达越高。CD200 R主要表达于浸润的巨噬细胞，可能与肝损伤有关。此外，与CD 200 R低表达的患者相比，CD 200 R高表达的患者的总体生存率和无复发生存率均显着较低。我们的研究结果表明，CD200 R作为一个有前途的预后指标，在预测复发率升高和生存率降低，并在治疗肝细胞癌的潜在治疗靶点的作用。(C)2016年欧洲免疫学会联合会。Elsevier B.V.出版，保留所有权利。
The inhibitory CD200:CD200 receptor axis is essential in preventing inflammatory responses during early microbial infection. It was reported in several tumor models that CD200 expression is closely associated to tumor progression and the blockade of this pathway may restore anti-tumor responses. Our study for the first time investigates the role of CD200:CD200R axis in relation to tumor progression and prognosis of human hepatocellular carcinoma. CD200 and CD200R protein expressions were evaluated by immunostaining on liver tissue specimens and we found higher expressions of CD200 and CD200R in HCC patients comparing to healthy controls. CD200 expresses in peritumoral, peritumoral stroma and intratumoral regions of HCC while CD200R predominantly expresses in peritumoral stroma. Furthermore, protein intensity of CD200R is positively associated to the diameter of tumor and alpha-fetoprotein level, in addition, patients with higher pathological grade and absence of tumor capsule exhibit higher CD200R expression. CD200R predominantly expresses on infiltrating macrophages and may associate with liver injury. Moreover, both overall and recurrence-free survival rates are significantly lower in patients with high CD200R expression comparing to those with low CD200R expression. Our findings suggest a promising role of CD200R as a prognostic marker in predicting elevated recurrence and reduced survival, and a potential therapeutic target in treating hepatocellular carcinoma. (C) 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.